Cambridge Investment Research Advisors’s Theriva Biologics TOVX Stock Holding History

Cambridge Investment Research Advisors’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-9	Closed	-$131K	–	1810
2016 Q3	$131K	Hold	9	–	–	﹤0.01%	1643
2016 Q2	$137K	Hold	9	–	–	﹤0.01%	1446
2016 Q1	$179K	Hold	9	–	–	﹤0.01%	1424
2015 Q4	$181K	Hold	9	–	–	﹤0.01%	1401
2015 Q3	$186K	Buy	9 +3	+50%	+$73.8K	0.01%	1271
2015 Q2	$145K	Hold	6	–	–	﹤0.01%	1326
2015 Q1	$111K	Buy	+6	New	+$107K	﹤0.01%	1335

Other funds holding TOVX

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Cambridge Investment Research Advisors's TOVX Position: Q4 2016 in Review

Cambridge Investment Research Advisors sold out of Theriva Biologics (TOVX) in Q4 2016, closing a stake of 9 shares — an estimated $131K sold.

Cambridge Investment Research Advisors first reported a position in TOVX in Q1 2015 and held it in 7 quarters. The position peaked at $186K in Q3 2015. 70 funds tracked by Wall St. Rank hold TOVX as of Q4 2016.

Cambridge Investment Research Advisors reported no remaining Theriva Biologics position as of Q4 2016 after selling out during the quarter.
Cambridge Investment Research Advisors sold 9 Theriva Biologics shares in Q4 2016, an estimated $131K.
Cambridge Investment Research Advisors first reported a position in Theriva Biologics in Q1 2015 and held it in 7 quarters.
Cambridge Investment Research Advisors's Theriva Biologics position peaked at $186K in Q3 2015.
70 funds tracked by Wall St. Rank held Theriva Biologics as of Q4 2016.

Based on Cambridge Investment Research Advisors's 13F filing for Q4 2016, filed 13 Feb 2017.